Skip to main content

Cefepime and Ceftazidime Safety in Hospitalized Infants.

Publication ,  Journal Article
Arnold, CJ; Ericson, J; Cho, N; Tian, J; Wilson, S; Chu, VH; Hornik, CP; Clark, RH; Benjamin, DK; Smith, PB ...
Published in: Pediatr Infect Dis J
September 2015

BACKGROUND: Cefepime and ceftazidime are cephalosporins used for the treatment of serious Gram-negative infections. These cephalosporins are used off-label in the setting of minimal safety data for young infants. METHODS: We identified all infants discharged from 348 neonatal intensive care units managed by the Pediatrix Medical Group between 1997 and 2012 who were exposed to either cefepime or ceftazidime in the first 120 days of life. We reported clinical and laboratory adverse events occurring in infants exposed to cefepime or ceftazidime and used multivariable logistic regression to compare the odds of seizures and death between the 2 groups. RESULTS: A total of 1761 infants received 13,293 days of ceftazidime, and 594 infants received 4628 days of cefepime. Laboratory adverse events occurred more frequently on days of therapy with ceftazidime than with cefepime (373 vs. 341 per 1000 infant days, P < 0.001). Seizure was the most commonly observed clinical adverse event, occurring in 3% of ceftazidime-treated infants and 4% of cefepime-treated infants (P = 0.52). Mortality was similar between the ceftazidime and cefepime groups (5% vs. 3%, P = 0.07). There was no difference in the adjusted odds of seizure [odds ratio (OR) = 0.96 (95% confidence interval: 0.89-1.03)] or the combined outcome of mortality or seizures [OR = 1.00 (0.96-1.04)] in infants exposed to ceftazidime versus those exposed to cefepime. CONCLUSIONS: In this cohort of infants, cefepime was associated with fewer laboratory adverse events than ceftazidime, although this may have been due to a significant difference in clinical exposures and severity of illness between the 2 groups. There was no difference in seizure risk or mortality between the 2 drugs.

Duke Scholars

Published In

Pediatr Infect Dis J

DOI

EISSN

1532-0987

Publication Date

September 2015

Volume

34

Issue

9

Start / End Page

964 / 968

Location

United States

Related Subject Headings

  • Survival Analysis
  • Seizures
  • Pediatrics
  • Infant, Newborn
  • Infant
  • Humans
  • Hospitalization
  • Gram-Negative Bacterial Infections
  • Drug-Related Side Effects and Adverse Reactions
  • Cephalosporins
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Arnold, C. J., Ericson, J., Cho, N., Tian, J., Wilson, S., Chu, V. H., … Best Pharmaceuticals for Children Act--Pediatric Trials Network Administrative Core Committee, . (2015). Cefepime and Ceftazidime Safety in Hospitalized Infants. Pediatr Infect Dis J, 34(9), 964–968. https://doi.org/10.1097/INF.0000000000000778
Arnold, Christopher J., Jessica Ericson, Nathan Cho, James Tian, Shelby Wilson, Vivian H. Chu, Christoph P. Hornik, et al. “Cefepime and Ceftazidime Safety in Hospitalized Infants.Pediatr Infect Dis J 34, no. 9 (September 2015): 964–68. https://doi.org/10.1097/INF.0000000000000778.
Arnold CJ, Ericson J, Cho N, Tian J, Wilson S, Chu VH, et al. Cefepime and Ceftazidime Safety in Hospitalized Infants. Pediatr Infect Dis J. 2015 Sep;34(9):964–8.
Arnold, Christopher J., et al. “Cefepime and Ceftazidime Safety in Hospitalized Infants.Pediatr Infect Dis J, vol. 34, no. 9, Sept. 2015, pp. 964–68. Pubmed, doi:10.1097/INF.0000000000000778.
Arnold CJ, Ericson J, Cho N, Tian J, Wilson S, Chu VH, Hornik CP, Clark RH, Benjamin DK, Smith PB, Best Pharmaceuticals for Children Act--Pediatric Trials Network Administrative Core Committee. Cefepime and Ceftazidime Safety in Hospitalized Infants. Pediatr Infect Dis J. 2015 Sep;34(9):964–968.

Published In

Pediatr Infect Dis J

DOI

EISSN

1532-0987

Publication Date

September 2015

Volume

34

Issue

9

Start / End Page

964 / 968

Location

United States

Related Subject Headings

  • Survival Analysis
  • Seizures
  • Pediatrics
  • Infant, Newborn
  • Infant
  • Humans
  • Hospitalization
  • Gram-Negative Bacterial Infections
  • Drug-Related Side Effects and Adverse Reactions
  • Cephalosporins